← Back to All Filings

Boston Scientific Discloses Material Financial Impact & Guidance Risk from Cybersecurity Incident

High SignificanceSeptember 8, 2026 at 11:07:14 AM UTC

BOSTON SCIENTIFIC CORP

$BSX8-KCIK: 0000885725

Subscribe to track BSX

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Boston Scientific (NYSE: BSX) filed Form 8-K (Item 1.05) regarding its ongoing response to a cybersecurity incident identified on August 25, 2026.\n\nKey Highlights:\n- Financial Guidance Impact: The incident is determined likely to have a material impact on Q3 and FY 2026 operating results; the company stated it is unlikely to meet previously issued Q3 and FY 2026 net sales growth and adjusted EPS guidance.\n- Operational Status: Distribution network substantially restored; sterilization and manufacturing operations have resumed across most global facilities.\n- Long-Term Outlook: No material impact expected on long-term financial condition.\n- Next Update: Full updated outlook will be provided on the Q3 2026 earnings call on October 28, 2026.

Comprehensive Analysis

Item 1.05 Material Cybersecurity Incident Update

Boston Scientific Corporation (NYSE: BSX) has provided a material update on the cybersecurity incident originally identified on August 25, 2026.

Key Findings & Operational Updates

  • Unauthorized Activity: The incident involved unauthorized activity leading to a network outage affecting operating systems and business applications, disrupting manufacturing and order shipments.
  • Containment & Restoration: As of September 7, 2026, no evidence of ongoing unauthorized access has been identified. Distribution networks are substantially restored, sterilization facilities are operational, and global manufacturing has resumed across most facilities.

Financial & Guidance Impact

  • Material Operating Impact: The company determined the disruption will likely have a material impact on results of operations for both the third quarter and full year 2026.
  • Guidance Withdrawn/Unlikely to Meet: Boston Scientific stated it is unlikely to achieve its previously issued Q3 and full-year 2026 net sales growth and adjusted EPS guidance (originally provided July 29, 2026).
  • Long-Term Financial Condition: The incident is not expected to materially impact long-term financial health.
  • Upcoming Outlook: A revised financial outlook will be provided during the Q3 2026 earnings call scheduled for October 28, 2026.
Topics:#BSX#Cybersecurity#GuidanceUpdate#SEC#MedTech

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is AI-generated from public SEC filings and may contain errors. It is for informational and educational purposes only and is not investment, legal, or tax advice.

The Filing Fool is not a registered investment adviser, broker-dealer, or financial planner. Nothing here is a recommendation or solicitation to buy, sell, or hold any security.

Always do your own due diligence and consult a licensed professional.